Intratio
Loading...
Skip to main content
Sign in Sign up
Model output · Signal date 2026-11-06

Monte Rosa Therapeutics, Inc. (GLUE) Stock Forecast Nov. 6, 2026

Analysis updated on Nov. 6, 2026 (UTC) · Total · absolute moveSwitch to Alpha · Nasdaq

Share
X LinkedIn Reddit WhatsApp Telegram
Embed badge
Unlock full AI forecasts
Rating · 90D Unlock rating and forecasts
90-day forecast Sign up free to reveal
30-day forecast Total
Rank in coverage of 4891 stocks scored
Rank correlation · 90D 10.0% Spearman, 357 dates
Market Cap $874M small-cap · #47 of 60 peers
Summary

Monte Rosa Therapeutics, Inc. (GLUE) stock forecast summary

Our AI scores Monte Rosa Therapeutics, Inc. every trading day against every stock it covers. Create a free account and follow it to see its rating and price target.

Monte Rosa Therapeutics, Inc. is a small-cap company with a market capitalization of $874M. It ranks number 47 by market capitalization among the 60 Biological Products, (No Diagnostic Substances) issuers in our coverage with a current forecast.

For GLUE, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 10.0%, measured on 357 forecast dates between 2022-08-19 and 2026-08-07 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is -1.0%, measured on 400 forecast dates between 2022-08-19 and 2026-10-07. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report

Expected absolute price move over the horizon, market included. This is the number a price target is built from. Ratings: strong buy ≥ +5.1%, buy ≥ +3.3%, sell < +1.7%, strong sell < +0.8% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-30 signals)

A free account shows the exact forecast, rating and rank of 3 tickers you follow, GLUE included.

Price

GLUE price chart and AI forecast

GLUE
Cross-section · 2026-10-30

How GLUE ranks among 4891 stocks

90D Total forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).

-4.0% 0 +7.9%

All daily signals →

Fundamentals · 2026-09-30

Monte Rosa Therapeutics, Inc. (GLUE) fundamentals

Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Biological Products, (No Diagnostic Substances) peers listed below that report each metric.

Valuation & Market

MetricGLUEIndustry medianRank
Market Cap $874M $2.40B 47/60
P/B Ratio 1.76x 4.76x 46/48
EPS $-1.40 – –
Book Value/Share $5.82 – –
Revenue/Share $0.67 – –
FCF/Share $-2.04 – –

Profitability & Margins

MetricGLUEIndustry medianRank
ROE -26.4% -32.3% 17/44
ROA -18.8% -22.2% 20/47
ROIC -23.7% -30.2% 21/52
Operating Margin -263.9% -35.4% 28/41
Net Margin -229.2% -34.5% 24/36
EBT Margin -227.4% -45.6% 28/43
Tax Rate -0.8% – –

Financial Health

MetricGLUEIndustry medianRank
Current Ratio 10.32x 5.23x 15/59
D/E Ratio 0.41x 0.39x 25/52
Financial Leverage 1.41x 1.40x 25/51
Working Capital $578M $440M 23/58

Cash Flow

MetricGLUEIndustry medianRank
Operating Cash Flow -$165M -$141M 35/56
Free Cash Flow -$174M -$127M 31/49
Capital Spending -$9M -$6M 29/49
OCF Growth YoY -210.9% 18.4% 15/16
FCF Growth YoY -220.2% 22.5% 15/16
FCF/Sales -305.2% -6.3% 26/32
CapEx/Sales 15.6% 3.0% 2/32

Operational Efficiency

MetricGLUEIndustry medianRank
Asset Turnover 0.08x 0.38x 29/37
Fixed Assets Turnover 2.0x 3.9x 27/38

Income Statement

MetricGLUEIndustry medianRank
Total Revenue $57M $405M 30/38
Operating Income -$151M -$180M 24/53
Net Income -$131M -$179M 18/47
R&D Expense $179M $207M 32/55

Dividend & Shareholder Information

MetricGLUEIndustry medianRank
Shares Outstanding 85M – –
Net Income Growth -725.3% 13.2% 11/11
EPS Growth -488.9% 11.5% 15/15

Balance Sheet Highlights (USD millions)

Total Current Assets$640M91.7% of assets
Cash & Short-term Investments$45M6.5% of assets
Total Liabilities$202M28.9% of assets
Short-term Debt$59M8.4% of assets
Quarterly Financial Reports

GLUE quarterly financials and insider trading

Industry Peers · Biological Products, (No Diagnostic Substances)

Monte Rosa Therapeutics, Inc. (GLUE) industry peers

Companies classified under the same SEC industry code as Monte Rosa Therapeutics, Inc. (Biological Products, (No Diagnostic Substances)): 60 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.

Reveal all forecasts · See exact % predictions for all competitors

Sign up free
Company 90-Day AI Forecast (Total) Market Cap P/E Ratio P/B Ratio
GLUE Monte Rosa Therapeutics, Inc. $874M – 1.8x
AMGN Amgen Inc $248.84B 26.7x 17.3x
GILD Gilead Sciences, Inc. $207.84B – 15.9x
MRNA Moderna, Inc. $96.40B – 14.3x
ARGX Argenx Se $55.37B 23.5x –
RVMD Revolution Medicines, Inc. $42.80B – 17.8x
BIIB Biogen Inc. $36.06B 105.1x 1.9x
BNTX Biontech Se $21.71B 2.2x –
EXEL Exelixis, Inc. $16.77B 24.7x 9.1x
NBIX Neurocrine Biosciences Inc $16.24B 23.4x 4.2x
HALO Halozyme Therapeutics, Inc. $13.96B 24.9x –
TECH Bio-Techne Corp $11.41B 62.6x 5.4x
QGEN Qiagen N.V. $11.03B 36.1x 2.9x
KYMR Kymera Therapeutics, Inc. $10.94B – 6.8x
RGEN Repligen Corp $10.77B – 5.2x
PCVX Vaxcyte, Inc. $9.21B – 3.7x
KRYS Krystal Biotech, Inc. $8.90B 40.8x 6.2x
IBRX Immunitybio, Inc. $8.49B – –
TWST Twist Bioscience Corp $7.56B – 17.0x
IMVT Immunovant, Inc. $5.86B – 8.0x
CGON Cg Oncology, Inc. $5.74B – 5.6x
KOD Kodiak Sciences Inc. $5.72B – 93.6x
SRRK Scholar Rock Holding Corp $5.54B – 21.8x
CRSP Crispr Therapeutics Ag $4.70B – 2.9x
ADPT Adaptive Biotechnologies Corp $4.28B – 24.3x
RLAY Relay Therapeutics, Inc. $3.95B – 4.8x
IOVA Iovance Biotherapeutics, Inc. $3.51B – 4.3x
TARS Tarsus Pharmaceuticals, Inc. $3.33B – 32.0x
DNLI Denali Therapeutics Inc. $3.15B – 3.4x
ADMA Adma Biologics, Inc. $2.96B 19.7x 6.8x
BEAM Beam Therapeutics Inc. $2.67B 369.6x 2.8x
COAG Hemab Therapeutics Holdings, Inc. $2.13B – 4.7x
VCEL Vericel Corp $2.10B 83.9x 5.5x
LIFE Atyr Pharma Inc $2.08B – 42.7x
RXRX Recursion Pharmaceuticals, Inc. $2.08B – 2.3x
REPL Replimune Group, Inc. $1.96B – 9.6x
BCRX Biocryst Pharmaceuticals Inc $1.95B – –
VIR Vir Biotechnology, Inc. $1.86B – 2.1x
MAZE Maze Therapeutics, Inc. $1.81B – 4.0x
MESO Mesoblast Ltd $1.81B – –
ALVO Alvotech $1.62B – –
NVAX Novavax Inc $1.61B 108.7x –
IMCR Immunocore Holdings Plc $1.46B – 3.5x
TSHA Taysha Gene Therapies, Inc. $1.33B – 3.4x
VOR Vor Biopharma Inc. $1.15B – –
CGEM Cullinan Therapeutics, Inc. $1.01B – 3.1x
ODTX Odyssey Therapeutics, Inc. $907M – 2.4x
IMTX Immatics N.V. $829M – –
MGTX Meiragtx Holdings Plc $817M 11.1x 3.8x
PRME Prime Medicine, Inc. $799M – 20.1x
SANA Sana Biotechnology, Inc. $700M – 3.9x
SLDB Solid Biosciences Inc. $699M – 2.0x
SLBT Sl Science Holding Ltd $679M – –
DNA Ginkgo Bioworks Holdings, Inc. $671M – 1.6x
AURA Aura Biosciences, Inc. $657M – 2.1x
FDMT 4d Molecular Therapeutics, Inc. $621M – 1.5x
DBVT Dbv Technologies S.A. $616M – 3.7x
CADL Candel Therapeutics, Inc. $615M – 4.9x
VALN Valneva Se $551M – –
ENTX Entera Bio Ltd. $518M 9.1x 71.3x

Where GLUE sits on the market map

Life Sciences · Biological Products, (No Diagnostic Substances)
Explore the map →
News

Monte Rosa Therapeutics, Inc. (GLUE) stock news

Oct. 01 Monte Rosa Therapeutics Says MRT-8102 Showed Biomarker Improvements in Phase 1 Study MT Oct. 01 HC Wainwright Initiates Monte Rosa Therapeutics at Buy With $25 Price Target MT Sep. 08 Top Midday Stories: GE Aerospace to Acquire Consolidated Precision Products; Qualcomm Issues Share Warrant to Amazon MT Sep. 08 Monte Rosa Therapeutics Initiates Phase 2 Clinical Study for Vav1-Directed Molecular Glue Degrader MRT-6160 CI Sep. 08 Monte Rosa to Receive $50 Million Milestone Payment From Novartis for Phase 2 Launch of MRT-6160 MT Aug. 24 Monte Rosa Therapeutics Doses First Patient in Phase 2 Prostate Cancer Study MT Aug. 24 Monte Rosa Therapeutics Doses First Patient In MODeFIRe-1 Phase 2 Study Of MRT-2359 In Combination With Apalutamide In Patients With AR Mutation-Positive Metastatic Castration-Resistant Prostate Cancer CI Aug. 06 Monte Rosa Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI

More news available

Sign up free to read all 9 news articles and stay updated on market developments.

Sign Up Free to Read More
FAQ

Monte Rosa Therapeutics, Inc. (GLUE) stock forecast FAQ

What is the Monte Rosa Therapeutics, Inc. (GLUE) stock forecast?

Our AI scores Monte Rosa Therapeutics, Inc. every trading day against every stock it covers. Create a free account and follow it to see its rating and price target.

How accurate are Monte Rosa Therapeutics, Inc. stock predictions?

For GLUE, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 10.0%, measured on 357 forecast dates between 2022-08-19 and 2026-08-07 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is -1.0%, measured on 400 forecast dates between 2022-08-19 and 2026-10-07. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report

How often are Monte Rosa Therapeutics, Inc. forecasts updated?

Monte Rosa Therapeutics, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Nov. 6, 2026.

Which companies are Monte Rosa Therapeutics, Inc.'s industry peers?

60 issuers in our coverage, GLUE included, share the SEC industry code Biological Products, (No Diagnostic Substances). The largest are: Amgen Inc (AMGN), Gilead Sciences, Inc. (GILD), Moderna, Inc. (MRNA), Argenx Se (ARGX), Revolution Medicines, Inc. (RVMD), Biogen Inc. (BIIB).

This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.

Intratio is a quantitative research firm specializing in systematic equity forecasting and portfolio optimization. We serve institutional investors, hedge funds, and family offices worldwide.

Quantitative research output, not investment advice.

Connect
English
Français
Español
العربية
简体中文
Deutsch
日本語
한국어
Português
Русский
Türkçe
हिन्दी
Bahasa Indonesia
Italiano

2018–2026 © Intratio. All Rights Reserved.

  • Visa
  • Mastercard
  • American Express
  • PayPal